Pridopidine for the treatment of Levodopa-induced Dyskinesia in patients with Parkinson’s disease
Objective: To assess the efficacy and safety of pridopidine in PD patients with Levodopa-induced dyskinesia (LID). Background: Pridopidine is a small molecule in clinical development…Levodopa Dose Equivalency for Opicapone and Safinamide
Objective: To provide a levodopa dose equivalency (LED) for opicapone and safinamide. Background: Tomlinson at al., provided a schedule to calculate LED of the different…PNPLA6-related Disorder With Expanded Phenotype Including Parkinsonism, Dystonia, And Abnormal Dopamine Transporter Imaging
Objective: To present a case of PNPLA6-related disorder with an expanded phenotype. Background: PNPLA6-related are autosomal recessive disorders with heterogeneous clusters of cerebellar ataxia, upper…Alpha-synuclein DNA methylation in CD45+ blood cells in Parkinson’s disease
Objective: We examined the methylation status of the DNA SNCA-intron1 at CD45+ blood cells in patients with sporadic Parkinson's disease (PD). Background: PD is a…Long term safety of levodopa/carbidopa infusion with ND0612: Results from a phase 2b, international, open-label study
Objective: The primary objective of this long-term study was to evaluate the safety and tolerability of a 24-hour regimen and a 16-hour ‘waking day’ regimen…Opicapone and entacapone as add-on therapy to the treatment of infusions of levodopa-carbidopa intestinal gel in patients with advanced Parkinson’s disease
Objective: To study the effect of COMT inhibitors (opicapone and entacapone) in Parkinson's disease (PD) patients on levodopa-carbidopa intestinal gel (LCIG) and an insufficient control of…Motor- and Non-motor Symptoms in Patients Treated with 24-hour Daily Levodopa-Carbidopa Intestinal Gel Infusion: Analysis of the COSMOS Observational Study
Objective: Describe and compare demographic and clinical characteristics, motor, and non-motor symptoms for patients with advanced Parkinson’s disease (APD) by daily duration (<24 hours or…Altered interhemispheric synchrony in Parkinson’s disease patients with levodopa-induced dyskinesias
Objective: Our investigation aimed to explore interhemispheric functional alterations and its corresponding morphological synchronization changes. Background: Levodopa-induced dyskinesias are common motor complication of Parkinson’s disease…Rapid on-time onset and sustained improvements in motor states throughout the day following treatment with levodopa/carbidopa intestinal gel (LCIG) vs immediate-release levodopa/carbidopa oral capsules (LCIR)
Objective: To assess the speed of on-time onset and characterize the patterns of motor states throughout the day in advanced Parkinson’s disease patients treated with…Gut Microbiote Distinctive Features and Microbiota-Metabolome Profile in Parkinson’s Disease: Focus on Levodopa and LCIG
Objective: The aim of this work was to study the microbiome of PD patients, studying the effect of dopaminergic drugs mainly focusing on the effect…
- « Previous Page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- …
- 62
- Next Page »